GLPwatch
Papers (10588)
Page 173 of 177, ranked by citation count.
- Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.
- Tirzepatide and metformin effects on hunger and BMI in an adolescent with hyperphagia and severe obesity due to MC4R Deficiency: a case report.
- Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
- Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.
- Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity.
- Antidiabetikum vor neuer Karriere.
- Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.
- Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways.
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.
- How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.
- Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
- Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.
- Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.
- Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.
- GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.
- [Is there life after teduglutide?]
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data.
- Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
- Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.
- A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.
- GLP-1 receptor agonists in atherosclerotic cardiovascular disease and diabetes mellitus or obesity: investigation of the potential role in a German inpatient dataset.
- Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.
- [Among adults with cardiovascular disease and BMI≥27kg/m<sup>2</sup> but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?]
- Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document.
- GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.
- Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
- GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.
- Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study.
- Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.
- Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.
- Liquid Chromatography Evaluation of a Novel Graphitic Carbon Stationary Phase Using Glucagon-Like Peptide‑1 Analogs.
- Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
- Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.
- The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
- Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.
- GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.
- Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.
- Ozempic and dental therapy.
- Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.
- Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.
- Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025.
- Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.
- Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns.
- Chronic semaglutide alters ingestive behavior without impairing taste function in mice.
- [Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.]
- Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
- Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.
- A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist.
- Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1.
- Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.
- Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.
- [Effect of semaglutide treatment on the body weight and the glucose, insulin and thyroid hormone levels in aging rats with diet-induced obesity.]
- Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.
- ARPA-H bets big to foster drugs that thwart aging.
- Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.